| Patent application number | Description | Published |
|---|
| 20100052845 | Antitheft System For Vehicle - In a keyless entry system, a CPU in an ECU and a CPU in a remote control key change a function formula specified by primary function formula data stored in a memory and a function formula specified by primary function formula data stored in a memory to respective new function formulas. With this structure, function formulas used in the remote control key and the ECU can be changed to respective new function formulas. This makes it possible to enhance the safety of the keyless entry system because it is difficult to predict the function formulas used in the remote control key and the ECU. | 03-04-2010 |
| 20100231351 | SYSTEMS AND METHODS FOR CONTROLLING A SMART COMMUNICATION SYSTEM FOR A VEHICLE - A smart communication system and method for a vehicle includes a master switch for toggling smart functionality on and off. An actuation signal is received by a control unit corresponding to a particular vehicle function. The actuation signal indicates that a corresponding actuating operation is occurring. The control unit determines whether the master switch is in an ON position. A key fob of the vehicle is confirmed to be within a search field of the vehicle when the master switch is determined to be in the ON position. The particular vehicle function is actuated when the key fob is confirmed to be within the search field; otherwise, manual actuation of the particular vehicle function is required. | 09-16-2010 |
| 20110040424 | VEHICLE KEYLESS OPERATION SYSTEM AND METHOD - A keyless function system and method includes a portable device having a vehicle function actuator thereon for initiating operation of a vehicle function. The portable device transmits an actuation signal to the vehicle when the vehicle function actuator is actuated. The receiver onboard the vehicle receives the actuation signal from the portable device. A controller onboard the vehicle and operatively connected to the receiver determines at least one of: whether the vehicle is located at a predetermined location or whether the portable device is located less than a predetermined distance from the vehicle. The controller selectively commands performance of the vehicle function when the actuation signal is received by the receiver based on at least one of: whether the vehicle is at the predetermined location or the portable device is less than the predetermined distance from the vehicle. | 02-17-2011 |
| 20110140839 | METHOD AND SYSTEM FOR DISABLING PASSIVE ENTRY KEY LOCATED INSIDE A VEHICLE - A method for disabling a passive entry key includes receiving a search request into an electronic control unit (“ECU”) on a vehicle to search for a passive key inside a vehicle cabin; emitting a search signal via an antenna in communication with the ECU in response to the received search request; receiving a reply signal via the antenna from the passive key inside the vehicle cabin; and recording in a memory in communication with the ECU an identification of the passive key inside the vehicle cabin in response to the received reply signal. In this method for disabling a passive entry key, the search request can be initiated by an operator at an input device. A passive entry key system is also disclosed. | 06-16-2011 |
| 20110304449 | UNIQUE HEADER FORMAT FOR TPMS AND SMART ENTRY SYSTEM - A vehicle entry/tire pressure management system includes an ECU, tire sensors mounted in, on or adjacent respective tires of the vehicle, a portable transmission/reception unit configured to be carried by an operator of the vehicle, and an antenna mounted on the vehicle and in communication with the ECU. Each tire sensor is configured to transmit an RF signal. The portable transmission/reception unit can transmit RF signals for controlling operations of the vehicle including unlocking doors of the vehicle. The antenna is configured to transmit an LF tire sensor wake up field to wake up the tire sensors. The tire sensor wake up field includes a unique header format. The tire sensors only fully wake up upon receiving the unique header format. | 12-15-2011 |
| 20110304451 | LOCALIZATION OF TIRE FOR TPMS AND SMART ENTRY SYSTEM - A vehicle entry/tire pressure management system includes a plurality of tire sensors, a plurality of low frequency (“LF”) antennas and an ECU. Each tire sensor is mounted in a respective tire of the vehicle. Each LF antenna is mounted on the vehicle and is configured to transmit an LF field to wake up two tire sensors. Some antennas can also be configured to transmit a SMART entry LF search field to wake up a portable transmission/reception unit for keyless entry of the vehicle. The ECU is in communication with the tire sensors, via a receiver, and the LF antennas. The ECU is configured to receive identification signals from the respective tire sensors and to determine locations of the respective tire sensors based on which antenna woke up the tire sensor transmitting the respective identification signal and whether the respective identification signal matches other received identification signals. | 12-15-2011 |
| 20110304453 | MEMORIZING LOCATION OF TIRES IN TPMS AND SMART ENTRY SYSTEM - A vehicle system includes a plurality of tire sensors, a plurality of low frequency (“LF”) antennas and an ECU. Each tire sensor is mounted in a respective tire of the vehicle. Each LF antenna is mounted on the vehicle and is configured to transmit an LF field to wake up two tire sensors. The ECU is in communication with the tire sensors, via a receiver, and the LF antennas. The ECU is configured to receive identification signals from the respective tire sensors and to determine locations of the respective tire sensors based on which antenna woke up the tire sensor transmitting the respective identification signal and whether the respective identification signal matches other received identification signals. The ECU is further configured to store the identification signals in the memory with the identification signals being associated with the respective tire sensors that transmitted the identification signal. | 12-15-2011 |
| Patent application number | Description | Published |
|---|
| 20090197827 | Combination Therapy for Treatment of FIV Infection - The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor. | 08-06-2009 |
| 20090274725 | Materials and Methods for Detecting, Preventing, and Treating Retroviral Infection - The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans. | 11-05-2009 |
| 20120070489 | COMBINATION THERAPY FOR TREATMENT OF FIV INFECTION - The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor. | 03-22-2012 |
| Patent application number | Description | Published |
|---|
| 20090142806 | INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR - The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling. | 06-04-2009 |
| 20090298081 | METHODS OF TREATMENT UTILIZING BINDING PROTEINS OF THE INTERLEUKIN-21 RECEPTOR - The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders. | 12-03-2009 |
| 20100062448 | PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES - The present invention is based on the discovery that ζPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ζPKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of ζPKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy. | 03-11-2010 |
| 20110033451 | INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR - The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling. | 02-10-2011 |
